The European Commission’s proposal for a Regulation on Advanced Therapy Medicinal Products (ATPs) is a significant step towards EU-wide harmonization, clarity and certainty for tissue engineered products. But the new clarity comes at a significant cost to the medical devices industry.
Download the full publication now
Fill in the form to download the content
publication by
Anne Dupraz Poiseau
Executive Vice President
Stuart Mudge
Senior Consultant Product Development
All our resources 
